BioSpace News Archive

Immunovia announced that the consultation process regarding realigning its Swedish operations, announced on 19 January 2023, has been completed.

LEO Pharma Inc. today announced the Health Canada approval of Adtralza® (tralokinumab) for adolescent patients aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Design Therapeutics, Inc. today announced that João Siffert, M.D., president and chief executive officer, will participate in a fireside chat during the SVB Securities Virtual Global Biopharma Conference on Wednesday, February 15, 2023, at 5:00 p.m. ET.

BD (Becton, Dickinson and Company) (NYSE: BDX) today announced that it has received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV) to help combat illness in the current and future respiratory virus seasons.

Vapotherm, Inc. today announced preliminary unaudited fourth quarter and full year 2022 net results.

Mereo BioPharma Group plc today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 01:00pm GMT / 08:00am ET.

EuMentis Therapeutics Inc., a privately-held biopharmaceutical company developing novel therapeutics for the treatment of neuropsychiatric diseases, today announced it has received an award from the United States Department of Defense (DoD) to develop a novel small molecule therapeutic targeting the extrasynaptic N-methyl-D-aspartate receptor (NMDAR) for the treatment of traumatic brain injury or “TBI.”

Generian Pharmaceuticals, Inc. announced that it has achieved the first research milestones for two programs in development under its collaboration agreement with Mitobridge, Inc.

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023.

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst) Injection by the U.S. Centers for Medicare & Medicaid Services (CMS) effective as of April 1, 2023.